Plerixafor is an
immunostimulant that mobilizes hematopoietic stem cells in cancer patients.
A chitosan derivative, glycated chitosan (GC), has been used as an
immunostimulant for cancer treatment in laser immunotherapy.
The alliance designed Fibosel[R], which has become today an
immunostimulant of reference with worldwide uses in a variety of animal species, especially aquatic species and young and breeding monogastric animals.
Andrographis contains andrographolide, a component that has shown effective
immunostimulant and antiinflammatory properties that may assist in relieving uncomplicated URTI.
Including more than one
immunostimulant within an adjuvant has the capacity to improve the quality of the immune response to a vaccine.
David Claxton at Penn State University (State College, PA) for the development of
immunostimulant and therapeutic vaccine approaches for the treatment of acute myelogenous leukemia (AML).
Carrington is a research-based biopharmaceutical company currently utilizing naturally-occurring polysaccharides to produce Acemannan
Immunostimulant, an injectable biologic for the treatment of fibrosarcoma in cats and dogs; Acemannan Hydrogel used in products for radiation dermatitis, and other wound and oral care applications; and a variety of polysaccharide raw materials for use in dietary supplement formulations.
Carrington currently holds approximately 120 patents, issued and pending, in 26 countries under which it manufactures its drug product Aliminase currently in Phase III clinical trials for the treatment of ulcerative colitis; Acemannan
Immunostimulant, an injectable as an adjunct for the treatment of fibrosarcoma in dogs and cats; raw materials, such as Manapol Powder used in a variety of consumer and nutraceutical products; and acemannan hydrogel used in Carrington's proprietary wound care products.
Pink Sheets: ATKJ), has improved Tubercin T-5 an
immunostimulant.
Amgen's blockbuster brands Neulasta (pegfilgrastim) and Neupogen (filgrastim) dominated the
immunostimulant market in 2007, with sales of $3.
The data will cover the consistency in multiple species of JuvImmune
immunostimulant and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.
6 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that it has begun dosing in a Phase 1/2 study that will assess the safety and dose-sparing capability of the company's
immunostimulant patch when used in combination with an injected H5N1 influenza vaccine.
